Celyad Oncology SA - American Depositary Shares (CYAD) earnings
Quarterly and annual CYAD reports and results, each read against the price at its own news timestamp. Back to the CYAD overview →
2 measured CYAD earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook | Press release | — | — | |
| Celyad Oncology reports third quarter 2023 financial results and recent business highlights | Press release | — | — |
Keep exploring
More CYAD: analyst actions → · SEC filings → · CYAD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IMV Inc. - Common Shares (IMV) | 508 | -0.36% | 36% |
| CAMBREX (CBM) | 505 | 0.00% | 49% |
| DELMAR PHARMACEUTICALS (DMPI) | 504 | -0.13% | 38% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 504 | -0.09% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.